

Alessandro Ferrari

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8328894/alessandro-ferrari-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27
papers

872
citations

13
h-index

29
g-index

32
ext. papers

1,190
ext. citations

7.6
avg, IF

4.37
L-index

#	Paper	IF	Citations
27	Immunity to SARS-CoV-2 up to 15 months after infection.. <i>IScience</i> , 2022 , 25, 103743	6.1	15
26	SARS-CoV-2 variants inactivation of plasma units using a riboflavin and ultraviolet light-based photochemical treatment.. <i>Transfusion and Apheresis Science</i> , 2022 , 103398	2.4	0
25	Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy. <i>Internal and Emergency Medicine</i> , 2021 , 16, 1141-1152	3.7	1
24	Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients. <i>Viruses</i> , 2021 , 13,	6.2	1
23	SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. <i>Nature Communications</i> , 2021 , 12, 6032	17.4	16
22	Macrophages and Monocytes: "Trojan Horses" in COVID-19. <i>Viruses</i> , 2021 , 13,	6.2	3
21	EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 315-319	10.5	22
20	Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 914.e1-914.e4	9.5	1
19	Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma. <i>Transfusion Clinique Et Biologique</i> , 2021 , 29, 101-101	1.9	0
18	SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1029-1034	9.5	19
17	Residual SARS-CoV-2 RNA in nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine always justified?. <i>International Journal of Infectious Diseases</i> , 2021 , 102, 299-302	10.5	11
16	Characterization of Varicella-Zoster (VZV) Specific T Cell Response in Healthy Subjects and Transplanted Patients by Using Enzyme Linked Immunospot (ELISpot) Assays. <i>Vaccines</i> , 2021 , 9,	5.3	2
15	Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	11
14	Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo Covid19 Registry (SMACORE). <i>Microorganisms</i> , 2020 , 8,	4.9	157
13	Emergency Department and Out-of-Hospital Emergency System (112-AREU 118) integrated response to Coronavirus Disease 2019 in a Northern Italy centre. <i>Internal and Emergency Medicine</i> , 2020 , 15, 825-833	3.7	31
12	Lack of SARS-CoV-2 RNA environmental contamination in a tertiary referral hospital for infectious diseases in Northern Italy. <i>Journal of Hospital Infection</i> , 2020 ,	6.9	39
11	Rapid response to COVID-19 outbreak in Northern Italy: how to convert a classic infectious disease ward into a COVID-19 response centre. <i>Journal of Hospital Infection</i> , 2020 ,	6.9	22

10	Performance of VivaDiag COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. <i>Journal of Medical Virology</i> , 2020 , 92, 1724-1727	19.7	152
9	SARS Cov-2 infection in a renal-transplanted patient: A case report. <i>American Journal of Transplantation</i> , 2020 , 20, 1882-1884	8.7	67
8	Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. <i>Eurosurveillance</i> , 2020 , 25,	19.8	86
7	Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. <i>Eurosurveillance</i> , 2020 , 25,	19.8	114
6	Severe acute respiratory syndrome coronavirus 2 RNA contamination of inanimate surfaces and virus viability in a health care emergency unit. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1094.e1-1094.e5	9.5	86
5	Low risk for SARS-CoV2 symptomatic infection and early complications in paediatric patients during the ongoing CoVID19 epidemics in Lombardy. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1569-1571	9.5	2
4	Detection of the SARS-CoV-2 in different biologic specimens from positive patients with COVID-19, in Northern Italy. <i>Pediatric Allergy and Immunology</i> , 2020 , 31, 72-74	4.2	3
3	Immunity to SARS-CoV-2 up to 15 months after infection		3
2	SARS-CoV-2 mRNA vaccine BNT162b2 elicited a robust humoral and cellular response against SARS-CoV-2 variants.		5
1	SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers		1